> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Egalet sNDA Seeks Abuse-deterrent Claim for Oxaydo
- URL: https://www.fdaweb.com/egalet-snda-seeks-abuse-deterrent-claim-for-oxaydo/
- Published: 2016-12-01T12:00:00.000Z
- Updated: 2026-09-14T21:51:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137467

Egalet Corp. has filed a supplemental NDA for Oxaydo (oxycodone HCl) tablets for an abuse-deterrent label claim for the intravenous route of abuse. The sNDA includes Category 1 *in vitro* data that demonstrate Oxaydo resists extraction of oxycodone and, based on its gelling properties, is more difficult to draw into a syringe compared to a non-abuse-deterrent immediate-release oxycodone comparator, the company says. Oxaydo is an immediate-release oral formulation of oxycodone HCl indicated for managing acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.